C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome

European Journal of Human Genetics

Volumn 20, Issue 8, 2012, Pages 870-877

  Klüppel, Michael ^a,b   Samavarchi Tehrani, Payman ^c   Liu, Kela ^d   Wrana, Jeffrey L ^c   Hinek, Aleksander ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

C4ST 1; chondroitin sulfate; CHST11; Costello syndrome; HRAS

Indexed keywords

CARBOHYDRATE SULFOTRANSFERASE 11; CHONDROITIN; CHONDROITIN 4 SULFATE; CHONDROITIN 4 SULFOTRANSFERASE 1; MESSENGER RNA; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COSTELLO SYNDROME; FIBROBLAST; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; INFANT; ONCOGENE H RAS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SULFATION;

CELLS, CULTURED; CHONDROITIN; COSTELLO SYNDROME; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; SULFOTRANSFERASES;

EID: 84864120796     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.12     Document Type: Article

References (45)

1. Costello JM: A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 1977; 13: 114-118. (Pubitemid 8158638)
2. Costello JM: Costello syndrome: update on the original cases and commentary. Am J Med Genet 1996; 62: 199-201.
3. Digilio MC, Sarkozy A, Capolino R et al: Costello syndrome: clinical diagnosis in the first year of life. Eur J Pediatr 2008; 167: 621-628. (Pubitemid 351503496)
4. Hennekam RC: Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 2003; 117C: 42-48. (Pubitemid 37063630)
5. Johnson JP, Golabi M, Norton ME et al: Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr 1998; 133: 441-448. (Pubitemid 28413632)
6. Mancini GM, van Diggelen OP, Kleijer WJ et al: Studies on the pathogenesis of Costello syndrome. J Med Genet 2003; 40: e37.
7. Rauen KA, Hefner E, Carrillo K et al: Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A 2008; 146A: 1205-1217. (Pubitemid 351628610)
8. Zenker M: Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr Opin Pediatr 2011; 23: 443-451.
9. Gripp KW: Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 2005; 137C: 72-77. (Pubitemid 41113664)
10. Aoki Y, Niihori T, Kawame H et al: Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37: 1038-1040. (Pubitemid 41486653)
11. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA: HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 2006; 140: 8-16. (Pubitemid 43054029)
12. Gripp KW, Lin AE, Stabley DL et al: HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 2006; 140: 1-7. (Pubitemid 43054028)
13. Kerr B, Delrue MA, Sigaudy S et al: Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 2006; 43: 401-405.
14. Kratz CP, Niemeyer CM, Zenker M: An unexpected new role of mutant Ras: perturbation of human embryonic development. J Mol Med (Berl) 2007; 85: 227-235.
15. Rauen KA: HRAS and the Costello syndrome. Clin Genet 2007; 71: 101-108. (Pubitemid 46189213)
16. Sol-Church K, Stabley DL, Demmer LA et al: Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. Am J Med Genet A 2009; 149A: 315-321.
17. Zampino G, Pantaleoni F, Carta C et al: Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 2007; 28: 265-272.
18. Rauen KA, Banerjee A, Bishop WR et al: Costello and cardio-facio- cutaneous syndromes: moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet 2011; 157: 136-146.
19. Tidyman WE, Rauen KA: Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10: e37.
20. Habuchi O: Diversity and functions of glycosaminoglycan sulfotransferases. Biochim Biophys Acta 2000; 1474: 115-127. (Pubitemid 30162976)
21. Klüppel M: The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog Mol Biol Transl Sci 2010; 93: 113-132.
22. Kusche-Gullberg M, Kjellen L: Sulfotransferases in glycosaminoglycan biosynthesis. Curr Opin Struct Biol 2003; 13: 605-611. (Pubitemid 37244116)
23. Sugahara K, Kitagawa H: Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr Opin Struct Biol 2000; 10: 518-527.
24. Klüppel M, Wight TN, Chan C, Hinek A, Wrana JL: Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 2005; 132: 3989-4003. (Pubitemid 41410261)
25. Properzi F, Carulli D, Asher RA et al: Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia. Eur J Neurosci 2005; 21: 378-390. (Pubitemid 40204241)
26. Ricciardelli C, Quinn DI, Raymond WA et al: Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res 1999; 59: 2324-2328. (Pubitemid 29242276)
27. Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, Marshall VR, Horsfall DJ: Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 2009; 69: 761-769.
28. Sakko AJ, Butler MS, Byers S et al: Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol Biomarkers Prev 2008; 17: 2488-2497.
29. Suwiwat S, Ricciardelli C, Tammi R et al: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004; 10: 2491-2498. (Pubitemid 38445711)
30. Teng YH, Tan PH, Chia SJ et al: Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod Pathol 2008; 21: 893-901. (Pubitemid 351896665)
31. Vijayagopal P, Figueroa JE, Levine EA: Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J Surg Oncol 1998; 68: 250-254. (Pubitemid 28390182)
32. Klüppel M, Vallis KA, Wrana JL: A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling. Mech Dev 2002; 118: 77-89. (Pubitemid 35292123)
33. Lopes CC, Toma L, Pinhal MA et al: EJ-ras oncogene transfection of endothelial cells upregulates the expression of syndecan-4 and downregulates heparan sulfate sulfotransferases and epimerase. Biochimie 2006; 88: 1493-1504. (Pubitemid 44667211)
34. Romaris M, Villena J, Molist A, Heredia A, Bassols A: Ras transformation alters the composition of extracellular matrix proteoglycans in rat fibroblasts. Biochem Biophys Res Commun 1994; 200: 925-932. (Pubitemid 24146050)
35. Hinek A, Smith AC, Cutiongco EM, Callahan JW, Gripp KW, Weksberg R: Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67-kD elastin-binding protein. Am J Hum Genet 2000; 66: 859-872. (Pubitemid 30470489)
36. Hinek A, Teitell MA, Schoyer L et al: Myocardial storage of chondroitin sulfatecontaining moieties in Costello syndrome patients with severe hypertrophic cardiomyopathy. Am J Med Genet A 2005; 133A: 1-12. (Pubitemid 40175556)
37. Jorge AA, Malaquias AC, Arnhold IJ, Mendonca BB: Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res 2009; 71: 185-193.
38. Gremer L, Merbitz-Zahradnik T, Dvorsky R et al: Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 2011; 32: 33-43.
39. Niihori T, Aoki Y, Okamoto N et al: HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome. J Hum Genet 2011; 56: 707-715.
40. Hatamochi A, Nagayama H, Kuroda K et al: Costello syndrome with decreased gene expression of elastin in cultured dermal fibroblasts. Dermatology 2000; 201: 366-369. (Pubitemid 32037570)
41. Hinek A, Braun KR, Liu K, Wang Y, Wight TN: Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 2004; 164: 119-131. (Pubitemid 38364597)
42. Mori M, Yamagata T, Mori Y et al: Elastic fiber degeneration in Costello syndrome. Am J Med Genet 1996; 61: 304-309.
43. Tatano Y, Fujinawa R, Kozutsumi Y et al: Tropoelastin regulates chemokine expression in fibroblasts in Costello syndrome. Biochem Biophys Res Commun 2008; 372: 681-687.
44. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689. (Pubitemid 19213607)
45. Uebelhart D: Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 2008; 16(Suppl 3): S19-S21.